BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Bello DM, Dematteo RP, Ariyan CE. The GIST of targeted therapy for malignant melanoma. Ann Surg Oncol 2014;21:2059-67. [PMID: 24531699 DOI: 10.1245/s10434-013-3373-z] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
Number Citing Articles
1 Cree IA, Charlton P. Molecular chess? Hallmarks of anti-cancer drug resistance. BMC Cancer. 2017;17:10. [PMID: 28056859 DOI: 10.1186/s12885-016-2999-1] [Cited by in Crossref: 108] [Cited by in F6Publishing: 96] [Article Influence: 21.6] [Reference Citation Analysis]
2 Sakaizawa K, Ashida A, Uchiyama A, Ito T, Fujisawa Y, Ogata D, Matsushita S, Fujii K, Fukushima S, Shibayama Y, Hatta N, Takenouchi T, Uehara J, Okuyama R, Yamazaki N, Uhara H. Clinical characteristics associated with BRAF, NRAS and KIT mutations in Japanese melanoma patients. Journal of Dermatological Science 2015;80:33-7. [DOI: 10.1016/j.jdermsci.2015.07.012] [Cited by in Crossref: 57] [Cited by in F6Publishing: 46] [Article Influence: 8.1] [Reference Citation Analysis]
3 Yan J, Chen D, Chen X, Sun X, Dong Q, Hu C, Zhou F, Chen W. Downregulation of lncRNA CCDC26 contributes to imatinib resistance in human gastrointestinal stromal tumors through IGF-1R upregulation. Braz J Med Biol Res. 2019;52:e8399. [PMID: 31166382 DOI: 10.1590/1414-431x20198399] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
4 Yang HM, Hsiao SJ, Schaeffer DF, Lai C, Remotti HE, Horst D, Mansukhani MM, Horst BA. Identification of recurrent mutational events in anorectal melanoma. Mod Pathol. 2017;30:286-296. [PMID: 27739435 DOI: 10.1038/modpathol.2016.179] [Cited by in Crossref: 31] [Cited by in F6Publishing: 30] [Article Influence: 5.2] [Reference Citation Analysis]
5 Gao NA, Guo NJ, Yu WZ, Wang XX, Sun JR, Yu N, Liu RT, Liu XD, Liu ZY, Feng R. Synchronous occurrence of gastrointestinal stromal tumor and acute myeloid leukemia: A case report and review of the literature. Oncol Lett. 2016;11:2977-2980. [PMID: 27123049 DOI: 10.3892/ol.2016.4353] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
6 Patel M, Eckburg A, Gantiwala S, Hart Z, Dein J, Lam K, Puri N. Resistance to Molecularly Targeted Therapies in Melanoma. Cancers (Basel) 2021;13:1115. [PMID: 33807778 DOI: 10.3390/cancers13051115] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Hintzsche JD, Gorden NT, Amato CM, Kim J, Wuensch KE, Robinson SE, Applegate AJ, Couts KL, Medina TM, Wells KR, Wisell JA, McCarter MD, Box NF, Shellman YG, Gonzalez RC, Lewis KD, Tentler JJ, Tan AC, Robinson WA. Whole-exome sequencing identifies recurrent SF3B1 R625 mutation and comutation of NF1 and KIT in mucosal melanoma. Melanoma Res 2017;27:189-99. [PMID: 28296713 DOI: 10.1097/CMR.0000000000000345] [Cited by in Crossref: 68] [Cited by in F6Publishing: 37] [Article Influence: 17.0] [Reference Citation Analysis]
8 Vazquez Vde L, Vicente AL, Carloni A, Berardinelli G, Soares P, Scapulatempo C, Martinho O, Reis RM. Molecular profiling, including TERT promoter mutations, of acral lentiginous melanomas. Melanoma Res 2016;26:93-9. [PMID: 26709572 DOI: 10.1097/CMR.0000000000000222] [Cited by in Crossref: 37] [Cited by in F6Publishing: 17] [Article Influence: 7.4] [Reference Citation Analysis]
9 Smith DA, Pfau D, Tirumani SH, Alessandrino F, Sadri N, Ramaiya NH. Decoding the Genomic Report for Radiologists. AJR Am J Roentgenol 2020;214:949-61. [PMID: 32182095 DOI: 10.2214/AJR.19.21677] [Reference Citation Analysis]